Invitation
8th Michael J. Marberger (MJM)
Annual Meeting
Frontiers in Urology
Friday, 16th December 2022, 1.00 pm
Van Swieten Saal, Medical University of Vienna
Van-Swieten-Gasse 1a, 1090 Vienna
www.meduniwien.ac.at/frontiers

Contact
Department of Urology
MedUni Vienna/University Hospital Vienna
Waehringer Guertel 18-20, 1090 Vienna, Austria
Phone: +43 (0)1 40400-26150
Fax: +43 (0)1 40400-23320
E-Mail: shahrokh.shariat@meduniwien.ac.at
www.meduniwien.ac.at/urology

In cooperation with

Please be aware that photographs and/or video footage will be taken at the event. These may be used for the purpose of documenting or reporting the event and published in print and online media, on various social media platforms and on MedUni Vienna’s website.

Please send your registration to mjm@meduniwien.ac.at

Coverfoto: Elnur/Shutterstock.com

Bronze Partner
AstraZeneca
Bristol Myers Squibb
ETHICON
MERCK
Myriant genetix
OLYMPUS
SANDOZ 
I Novartis Division

Copper Partner
Canon
Duverier MedTech
FERRING Pharmaceutical
IPSEN
Nino Medicus

Silver Partner

Gold Partner

Platinum Partner

In alphabetic order
The 8th Michael J. Marberger Annual Meeting is a hybrid, intensive, interactive, half-day educational program that brings together renowned international experts to discuss Frontiers in Urology.

The meeting will focus on key clinical topics in the management of urologic diseases including prostate, bladder and kidney cancers. On 16th December, state-of-the-art lectures will provide clinicians and scientists with an update of the breakthroughs of 2022 to maintain their high level of care and further optimize their outcomes.

Target Audience
This educational activity is directed toward urologists and other health care providers involved in the treatment and management of patients with urologic maladies.

Learning Objectives
At the conclusion of this activity, participants should be better prepared to:
• Describe the newest methods for diagnosis and information that can provide the rationale for clinical decision-making.
• Summarize recommendations that shape current strategies to care for patients.
• Develop multidisciplinary strategies to optimize outcomes for patients.
• Assess recent practice-changing clinical trial findings concerning novel tools, compounds or strategies.
• Apply emerging clinical concepts to support the management in consideration of evolving treatment paradigms in the field.

See more at: www.meduniwien.ac.at/frontiers

Program
1.00 – 1.05 pm
Opening
Shahrokh F. Shariat, Medical University of Vienna/ University Hospital Vienna, Austria

1.05 – 2.45 pm
Session 1: General urology

Testosterone Replacement Therapy in Prostate Cancer patients, friend or foe
Bertrand Tombal, Université Catholique de Louvain (UCL), Brussels, Belgium

Minimal invasive stone management in 2022: What are the new game changers forcing the present frontiers?
Kemal Sarica, Biruni University, Istanbul, Türkiye

Updates on diagnosis and management of post prostatectomy incontinence
Sakineh Hajebrahimi, Tabriz University of Medical Sciences, Tabriz, Iran

The urologist vs the medical oncologist, who should manage advanced urologic cancers?
Brian Keith McNeill, The University Hospital of Brooklyn (UHB), New York City, USA

Thulium-Faserlaser (TFL) for stones. From bench to bedside
Dimitry Enikeev, I.M. Sechenov First Moscow State Medical University, Moscow, Russia

2.45– 3.05 pm
Break

3.05 – 4.45 pm
Session 2: Uro-oncology

Which is the most promising approach in BCG unresponsive NMIBC?
Marek Babjuk, Charles University, Hospital Motol, Prague, Czech Republic

Minimally invasive vs. open radical nephroureterectomy
Paolo Gontero, Università degli Studi di Torino, Italy

Fluorescence-guided laparoscopic partial adrenalectomy
Altuğ Tuncel, Ankara City Hospital, Ankara, Türkiye

Personalized therapy of advanced urothelial carcinoma: reality or fiction?
Maria De Santis, Charité - Universitätsmedizin Berlin, Germany

Lessons learned from recent trials in kidney cancer
Manuela Schmidinger, Medical University of Vienna/ University Hospital Vienna, Austria

4.45 – 5.05 pm
Coffee break

5.05 – 6.10 pm
Session 3: Prostate cancer

Prediction of therapy response in mCRPC
Péter Nyirády, Semmelweis University Urology Clinic, Budapest, Hungary

Focal Therapy for Prostate cancer: What is Old is New Again
Ganesh S. Palapattu, Michigan Medicine, University of Michigan, USA

Michael J. Marberger lecture “What is the future of Academic Urology?”
Bertrand Tombal, Université Catholique de Louvain (UCL), Brussels, Belgium

Wrap Up
Shahrokh F. Shariat, Medical University of Vienna/ University Hospital Vienna, Austria

See more at: www.meduniwien.ac.at/frontiers

This event will be approved by the Austrian Medical Chamber with DFP.